Eli Lilly diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the U.S., which means compounding pharmacies must stop making less expensive copycat versions in the ...

Can anyone stop Eli Lilly’s progress in the weight loss market?

Eli Lilly’s (LLY) leadership position in the weight-loss drug market remains solid, and the gradual narrowing of the prescription volume gap for oral GLP-1 drugs provides a positive signal for ...

Eli Lilly has a broad pipeline of weight-loss products that will help it maintain its lead in this area. The company should continue posting excellent financial results over the medium term. 10 stocks ...

Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its ​blockbuster Zepbound in a head-to ...